Bruker Corp (BRKRP) revenue by segment
BRKRPNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BRKR
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30308% above fair value
$445.11+5.48 (+1.25%)
Close on Nov 17, 2026Market cap $9.52BP/E –Yield –
Bruker Corp revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BSI CALID | $1.21B | $1.09B | $960.40M | $822.20M | $819.60M | $653.90M | – | – | – | – | 35.2% | +10.7% |
| BSI NANO | $1.08B | $1.10B | $941.90M | $787.00M | $697.50M | $556.10M | $632.70M | $568.10M | – | – | 31.6% | -1.3% |
| BSI BioSpin | $878.80M | $905.70M | $798.50M | $696.70M | $691.00M | $600.00M | $621.40M | $591.10M | – | – | 25.6% | -3.0% |
| BEST | $270.90M | $283.00M | $280.70M | $237.10M | $223.80M | $189.50M | $209.90M | $194.80M | $191.20M | $130.20M | 7.9% | -4.3% |
| Bruker NANO | – | – | – | – | $697.50M | $556.10M | $632.70M | $568.10M | – | – | – | – |
| Bruker CALID | – | – | – | – | $819.60M | $653.90M | $623.50M | $547.80M | – | – | – | – |
| BSI Life Science | – | – | – | – | $1.51B | $1.25B | $1.24B | $1.14B | $1.07B | $1.49B | – | – |
| BSI Material Science | – | – | – | – | – | – | $632.70M | $568.10M | $513.00M | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Unallocated Expenses | $364.80M | $264.90M | $109.40M | $72.90M | – | – | – | – | – | – | +37.7% |
| BSI CALID | $262.60M | $246.20M | $232.10M | $216.40M | $227.20M | $152.20M | – | – | – | – | +6.7% |
| BSI BioSpin | $156.50M | $216.60M | $211.20M | $187.70M | $158.20M | $121.60M | – | – | – | – | -27.7% |
| BSI NANO | $101.10M | $123.90M | $158.40M | $138.10M | $73.40M | $23.60M | $40.40M | $48.40M | – | – | -18.4% |
| BEST | $26.70M | $35.10M | $32.50M | $30.40M | $22.20M | $6.20M | $16.40M | $14.50M | $7.40M | $6.60M | -23.9% |
| BSI Life Science | – | – | – | – | $385.40M | $273.80M | $290.30M | $244.00M | $212.20M | $173.50M | – |
| BSI Material Science | – | – | – | – | – | – | $40.40M | $48.40M | $24.30M | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $2.77B | $2.76B | $2.46B | $2.11B | $2.02B | $1.64B | $1.74B | $1.58B | $1.48B | $1.35B | 80.5% | +0.3% |
| Service and other revenue | $670.10M | $607.20M | $506.90M | $420.80M | $7.40M | $6.00M | $5.50M | $7.30M | $8.20M | $11.20M | 19.5% | +10.4% |
| Service | – | – | $493.80M | $414.60M | $393.20M | $343.40M | $322.40M | $311.70M | $278.20M | $254.70M | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe excluding Germany | $950.20M | $873.00M | $699.70M | – | – | – | – | – | – | – | 27.7% | +8.8% |
| United States | $891.30M | $938.50M | $777.70M | $696.10M | $601.00M | $455.90M | $529.80M | $489.40M | $434.70M | $428.20M | 25.9% | -5.0% |
| Asia Pacific excluding China | $552.60M | $518.50M | $460.90M | – | – | – | – | – | – | – | 16.1% | +6.6% |
| China | $475.80M | $471.20M | $528.10M | $396.50M | $357.60M | $313.50M | – | – | – | – | 13.8% | +1.0% |
| Germany | $297.00M | $310.70M | $281.50M | $247.40M | $262.60M | $244.90M | $213.60M | $201.10M | $200.20M | $189.50M | 8.6% | -4.4% |
| Other | $269.60M | $254.50M | $216.60M | $190.40M | $167.10M | $137.80M | $173.00M | $155.70M | $151.20M | $142.10M | 7.8% | +5.9% |
| Asia Pacific | – | – | $460.90M | $408.40M | $371.50M | $315.60M | $651.00M | $549.20M | $514.80M | $458.10M | – | – |
| Rest of Europe | – | $873.00M | $699.70M | $591.90M | $658.10M | $519.80M | $505.20M | $500.20M | $465.00M | $393.40M | – | – |
| Rest of Asia Pacific | – | $518.50M | $460.90M | $408.40M | – | – | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Bruker's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes. The KPIs tab shows these segments next to Bruker's operating metrics, with full history, charts and a link to each filing.
Operating metrics
| Remaining performance obligations (RPO) | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | YoY |
|---|---|---|---|---|---|---|---|---|
| Remaining performance obligations (RPO) | $2.09B | $2.23B | $2.26B | $2.08B | $2.01B | $1.86B | $1.05B | -6.1% |
Counts and sizes Bruker tags in the notes of its 10-K and 10-Q filings (XBRL), as of the end of each period. Breakdowns follow the company's own labels; at most 15 are shown per metric.
See a number that looks wrong?